%PDF-1.4
%
22 0 obj
<>
endobj
19 0 obj
<>
endobj
76 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T15:45:47Z
2024-03-29T00:14:06-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T00:14:06-07:00
application/pdf
Heather
200156.dec
uuid:9d5e9d46-1dd1-11b2-0a00-2e09278d5b00
uuid:9d5e9d48-1dd1-11b2-0a00-1e0000000000
endstream
endobj
8 0 obj
<>
endobj
9 0 obj
<>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
86 0 obj
[90 0 R]
endobj
87 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
465 777 92 -27 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:12)Tj
0 Tw -45.7952 -0.0313 Td
(2652)Tj
ET
0 0 0 0 scn
/GS0 gs
103.25 59.75 407.5 -10.83 re
f*
0.5 w
103.25 59.75 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
-0.0224 Tw 10 0 0 10 54 713.1616 Tm
(sclerosis. Several studies have found an association between)Tj
0.1864 Tw 0 -1.2 TD
[(the S128A)-381.6 (E-selectin polymorphism and premature coro-)]TJ
0.095 Tw T*
(nary artery disease in the general population, especially in)Tj
0.021 Tw T*
(subjects < 40 years of age)Tj
0 Tw 6.5 0 0 6.5 158.7047 680.4615 Tm
[(1)56.7 (1,12)]TJ
0.0211 Tw 10 0 0 10 172.9609 677.1616 Tm
(. Given that accelerated ather-)Tj
-0.00011 Tc 0.1573 Tw -11.8961 -1.2 Td
(osclerosis is a recognized late feature of SLE)Tj
0 Tc 0 Tw 6.5 0 0 6.5 245.1916 668.4615 Tm
(13)Tj
0.1573 Tw 10 0 0 10 251.6916 665.1616 Tm
(, this may)Tj
-0.02699 Tw -19.7692 -1.2 Td
(also provide insight into the common immune/inflammatory)Tj
0.02499 Tw T*
(origins of both vascular pathologies.)Tj
-0.00011 Tc 0.3253 Tw 1.2 -1.2 Td
(This study has several limitations. First, our groups)Tj
0 Tc 0.11909 Tw -1.2 -1.2 Td
(contained relatively small numbers of patients; it is there-)Tj
0.041 Tw T*
(fore important that this finding be reproduced in other SLE)Tj
0.21919 Tw T*
(cohorts and explored in other ethnic subgroups. Second,)Tj
-0.00909 Tw T*
(while all patients fulfilled the classification criteria for SLE,)Tj
0.0455 Tw T*
(our data related only to the clinical features included in the)Tj
-0.00211 Tw T*
(ACR criteria and a profile of autoantibodies ever positive in)Tj
-0.0248 Tw T*
(these patients. Our study is limited in its ability to detect any)Tj
0.01511 Tc 0.35989 Tw T*
(associations of this polymorphism in distinct disease)Tj
0 Tc -0.0126 Tw T*
(subgroups. In addition, data on coronary artery disease were)Tj
-0.00571 Tw T*
[(not available. )55 (A)-189.1 (lar)17.8 (ger and more detailed study is now under)]TJ
-0.00011 Tc 0.02499 Tw T*
(way to explore these issues.)Tj
0 Tc 0.097 Tw 1.2 -1.2 Td
[(W)79.8 (e found an association of the )54.9 (A561C E-selectin poly-)]TJ
0.2569 Tw -1.2 -1.2 Td
[(morphism with SLE in 2 independent populations. )17.8 (This)]TJ
0.2271 Tw T*
(polymorphism may be directly implicated in the disease)Tj
0.16029 Tw T*
(susceptibility or it may be in linkage disequilibrium with)Tj
-0.00951 Tw T*
(another polymorphism in the vicinity of the E-selectin gene.)Tj
0.0927 Tw T*
(The pivotal role of E-selectin in leukocyte-endothelial cell)Tj
0.0757 Tw T*
(interactions may increase susceptibility to vascular inflam-)Tj
-0.00011 Tc 0.0591 Tw T*
(mation in SLE. Further studies are now needed to assess if)Tj
0 Tc 0.22749 Tw T*
(it also influences the clinical phenotype and particularly)Tj
0.0058 Tw T*
(whether it may increase susceptibility to accelerated athero-)Tj
-0.00011 Tc 0.02499 Tw T*
(sclerosis seen in SLE.)Tj
/TT2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT1 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 61 331.1616 Tm
[(1.)-875 (T)69.8 (sao BP)110.8 (, Cantor RM, Kalunian KC, et al. Evidence for linkage of a)]TJ
1.675 -1.25 Td
(candidate chromosome 1 region to human systemic lupus)Tj
0 -1.25 TD
(erythematosus. J Clin Invest 1997;99:725-31.)Tj
31.325 50.421 Td
[(2.)-875 (Bevilacqua MP)110.8 (. Endothelial-leukocyte adhesion molecules. )54.9 (Annu)]TJ
1.675 -1.25 Td
[(Rev Immunol 1993;1)36.9 (1:767-804.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (W)79.7 (ellicome SM, )17.7 (Thornhill MH, )17.7 (Thomas DS, Lanchbury JS, Panayi)]TJ
0 Tc 1.675 -1.25 Td
[(GS, Haskard DO. )54.8 (A)-219.8 (monoclonal antibody that detects a novel)]TJ
T*
(antigen on endothelial cells that is induced by tumour necrosis)Tj
T*
[(factor)39.8 (, IL-1 or lipopolysaccharide. J Immunol 1990;144:2558-65.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Simon SI, Hu )36.8 (Y)129.1 (,)-0.1 ( )17.7 (V)111 (estweber D, Smith CW)91.7 (. Neutrophil tethering on)]TJ
0 Tc 1.675 -1.25 Td
(E-selectin activates beta 2 integrin binding to ICAM-1 through a)Tj
T*
[(mitogen-activated protein kinase signal transduction pathway)64.9 (. )]TJ
T*
(J Immunol 2000;164:4348-58.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Binns RM, Licence ST)73.9 (, Harrison )54.8 (AA, Keelan ET)73.9 (, Robinson MK,)]TJ
1.675 -1.25 Td
(Hascard OD. In vivo E-selectin up regulation correlates early with)Tj
T*
[(infiltration of PMN, later with PBL)-238.2 (entry: Mabs block both. )54.8 (Am J)]TJ
T*
(Physiol Heart Circ Physiol 1996;39:H183-H193.)Tj
0 Tc -1.675 -1.25 Td
[(6.)-875 (W)79.8 (enzel K, Ernst M, Rohde K, Baumann G, Speer )54.8 (A. DNA)]TJ
1.675 -1.25 Td
(polymorphism in the adhesion molecule genes \227 a new risk for)Tj
T*
(early atherosclerosis. Hum Genet 1996;97:15-20.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Al-Ansary )54.8 (AS, Ollier )17.7 (WER, )17.7 (V)60 (illarreal J, Ordi J, )17.7 (T)69.7 (ech L-S, Hajeer)]TJ
1.675 -1.25 Td
[(AH. )17.7 (T)34.8 (umour necrosis factor receptor II exon 6 polymorphism in)]TJ
0 Tc T*
[(systemic lupus erythematosus. )17.7 (T)34.9 (issue )54.8 (Antigens 2000;55;97-9.)]TJ
-1.675 -1.25 Td
[(8.)-875 (Revelle BM, Scott D, Beck PJ. Single amino acid residues in the )]TJ
1.675 -1.25 Td
(E- and P-selectins epidermal growth factor domains can determine)Tj
T*
[(carbohydrate binding specificity)64.9 (. J Biol Chem 1996;271:16160-70.)]TJ
-1.675 -1.25 Td
[(9.)-875 (W)79.8 (enzel K, Stahn R, Speer )54.9 (A, et al. Functional characterization of)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(atherosclerosis-associated Ser128Ar)17.7 (g and Leu554Phe E-selectin)]TJ
0 Tc T*
(mutations. Biol Chem 1999;380:661-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Rao RM, Clarke JL, Robinson MK, Landis C, Haskard DO. )17.7 (The )]TJ
0 Tc 2.175 -1.25 Td
[(E-selectin S128A)-220.1 (polymorphism enhances tethering and firm)]TJ
T*
[(adhesion of myeloid cells lines under flow [abstract]. )54.8 (Arthritis)]TJ
T*
(Rheum 2000;43 Suppl:S89.)Tj
-2.1381 -1.25 Td
[(1)36.9 (1.)-875 (W)79.8 (enzel K, Felix S, Kleber FX, et al. E-selectin polymorphism and)]TJ
-0.00011 Tc 2.1381 -1.25 Td
[(atherosclerosis: an association study)64.8 (. Hum Mol Genet 1994;)]TJ
0 Tc 0 Tw T*
(3:1935-7.)Tj
0.0249 Tw -2.175 -1.25 Td
[(12.)-875 (Y)100.1 (e)0.1 ( SQ, Usher D, )17.7 (V)60.1 (i)0.2 (r)17.8 (gil D, Zhang LQ, )36.8 (Y)100.1 (ochim SE, Gupta R. )54.8 (A)-219.8 (pstI)]TJ
2.175 -1.25 Td
[(polymorphism detects the mutation of serine to ar)17.8 (ginine in CD 62E)]TJ
-0.00011 Tc T*
(gene \227 a risk factor for coronary artery disease. J Biomed Sci)Tj
0 Tc 0 Tw T*
(1999;6:18-21.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
69 0 obj
<>
endobj
81 0 obj
<>
endobj
26 0 obj
<>
endobj
30 0 obj
<>
endobj
46 0 obj
<>
endobj
45 0 obj
<>
endobj
63 0 obj
<>stream
HdVpTs͋XBHvdI .